Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18722290 | 0.84 | HTR2A (0.43) | HTR2AHTR2CHTR2BALDH1A1CYP1A2 | |
| SCHEMBL3673574 | 0.83 | HTR2A (0.52) | HTR2AHTR2CHTR2BALDH1A1CYP1A2 | |
| SCHEMBL28189819 | 0.82 | ACHE (0.55) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5682494 | 0.82 | MAOB (0.45) | HTR2AHTR2CHTR2BCYP1A2CYP3A4 | |
| SCHEMBL4450192 | 0.78 | HTR2C (0.49) | HTR2AHTR2CHTR2BSLC6A4SLC6A3 | |
| SCHEMBL9737051 | 0.78 | TRPA1 (0.43) | HTR2AHTR2CHTR2BALDH1A1CYP1A2 | |
| SCHEMBL8498806 | 0.78 | TRPA1 (0.43) | HTR2AHTR2CHTR2BALDH1A1CYP1A2 | |
| SCHEMBL21568497 | 0.75 | GRIA4 (0.42) | HTR2AHTR2CHTR2BALDH1A1CYP1A2 | |
| SCHEMBL28255464 | 0.75 | GRIA4 (0.46) | HTR2AHTR2CHTR2BALDH1A1CYP1A2 | |
| SCHEMBL16892913 | 0.75 | ESR2 (0.50) | HTR2AHTR2CHTR2BALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299111-A1 | (ALKYLPHENYL) ALKYLCYCLOHEXANE AND METHOD FOR PRODUCING (ALKYLPHENYL) ALKYLCYCLOHEXANE OR ALKYLBIPHENYL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-1908743-A1 | (ALKYLPHENYL)ALKYLCYCLOHEXANE AND METHOD FOR PRODUCING (ALKYLPHENYL)ALKYLCYCLOHEXANE OR ALKYLBIPHENYL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299111-A1 | (ALKYLPHENYL) ALKYLCYCLOHEXANE AND METHOD FOR PRODUCING (ALKYLPHENYL) ALKYLCYCLOHEXANE OR ALKYLBIPHENYL | CCNA2, ACACB, PARP8 | HTR2A 2578/4885HTR2C 2280/4885HTR2B 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.